Location
February 16, 2022 Virtual Meeting of Cleveland ACS
Oliver Glass, PhD Category Clinician in Rare Diseases at Pfizer, Adjunct Assistant Professor of Medicine Duke University
Therapeutic Advances in Rare Diseases: A Journey into DYRK1A
My passion is to drive advancements in the treatment of rare diseases and bring medicines to patients quicker. DYRK1A syndrome is an autosomal dominant disorder that affects approximately 500 individuals worldwide. Changes in the DYRK1A gene have been linked to intellectual disabilities, microcephaly, speech and language impairment, seizures, and autism. Learn more about DYRK1A and research opportunities at dyrk1a.org
Dr. Glass received his Bachelor’s in Molecular Genetics from The Ohio State University in 2005, his PhD in Pathology from Duke University in 2015, and his MHS in Clinical Research from Duke University in 2020. He served as Director of Research at Duke Health and Well Being and was an Assistant Professor of Medicine. He is currently Category Clinician in Rare Diseases, Director at Pfizer, and is an Adjunct Assistant Professor of Medicine at Duke University. No cost to register and participateRegistration: